Published in BMC Nephrol on August 15, 2015
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant (2016) 0.88
Percutaneous Nephrolithotomy under Ultrasound Guidance in Patients with Renal Calculi and Autosomal Dominant Polycystic Kidney Disease: A Report of 11 Cases. Adv Urol (2017) 0.75
Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy. Clinicoecon Outcomes Res (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis (2011) 2.05
Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int (2008) 1.84
Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 1.67
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2007) 1.65
Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int (2003) 1.65
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant (2012) 1.61
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int (2011) 1.44
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol (2006) 1.37
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol (2010) 1.36
Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol (2008) 1.33
Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol (2009) 1.23
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.21
The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther (2011) 1.17
Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol (2006) 1.15
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant (2013) 1.08
Renal and extrarenal manifestations of autosomal dominant polycystic kidney disease. Braz J Med Biol Res (2006) 1.06
Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. PLoS One (2014) 1.06
Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant (2011) 1.06
Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease. Kidney Int (2012) 1.01
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis (2013) 1.01
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis (2012) 1.01
Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis (2014) 0.99
No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2003) 0.99
Renal cell carcinoma in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2009) 0.92
The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM (2013) 0.90
Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant (2013) 0.90
Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 0.89
Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol Dial Transplant (2014) 0.89
Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2013) 0.87
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int (2013) 0.87
The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD. Nephrol Dial Transplant (2008) 0.86
Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease. Int Urol Nephrol (2010) 0.86
Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol (2012) 0.85
Patterns of autosomal dominant polycystic kidney diseases in black Africans. Saudi J Kidney Dis Transpl (2010) 0.85
Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. Am J Kidney Dis (2013) 0.85
Mass-screening for early detection of renal disease: benefits and limitations of self-testing for proteinuria. J Nephrol (2009) 0.83
Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol (2013) 0.83
Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol (2010) 0.82
Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study. Nephrol Dial Transplant (2011) 0.82
Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease. BMC Nephrol (2014) 0.81
Renal cystic disease (ADPKD and ARPKD). Nephrol Dial Transplant (2002) 0.81
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Ren Fail (2010) 0.81
Novel PKD1 and PKD2 mutations in Taiwanese patients with autosomal dominant polycystic kidney disease. J Hum Genet (2013) 0.81
Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS One (2014) 0.80
A comparison of the effects of losartan and ramipril on blood pressure, renal volume and progression in polycystic kidney disease: A 5-Year follow-up. Hippokratia (2012) 0.79
Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study. Transplant Proc (2009) 0.79
Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease. Nefrologia (2012) 0.78
Transcatheter arterial embolization using ethanol in a dialysis patient for contracting enlarged polycystic kidneys. Korean J Radiol (2010) 0.77
Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. Peptides (2013) 0.77
Update on autosomal dominant polycystic kidney disease. Minerva Med (2007) 0.76
Frequency and clinical profile of patients with polycystic kidney disease in southern Brazil. Ren Fail (2008) 0.76
Adult polycystic kidney disease: who needs hospital follow-up? Artif Organs (2012) 0.76